About Glycomine
We are developing a PMM2-CDG substrate replacement therapy. GLM101 is a mannose-1 phosphate treatment.
Company Details
Corporate & Operational Profile
Web & Domain Identity
Social & Network Presence
Company Milestones & Timeline
- Capital Raise
Raised $115,000,000 · Series-B
Backed by Advent Life Sciences
- Capital Raise
Raised $68,000,000 · Series-B
Backed by Abingworth
- Capital Raise
Raised $12,000,000 · Series-A
Backed by Chiesi Ventures
- Milestone
Company founded
San Carlos, United States
Investors & Backers
Funding History
Round backers: Advent Life Sciences
Round backers: Abingworth
Round backers: Chiesi Ventures
Founders & Leadership
Agnes Rafalko
Founder
Deirdre Foley
Director of R&D, Biology
Peter McWilliams
CEO
Rose Marino
Chief Medical Officer
Steven Axon
Chief Executive Officer
Press Coverage & Sources
fundraisingfox.com/companies/glycomine-2
businesswire.com/news/home/20210623005070/en/Glycomine-Closes-68-Million-Series-B-to-Advance-into-Clinical-Trials-a-Novel-Treatment-for-PMM2-CDG-a-Rare-Glycosylation-Disease
fiercebiotech.com/biotech/rare-disease-biotech-glycomine-raises-12m-help-from-chiesi-venture-arm
Recently Funded Biotech & Healthcare Startups
View allTesorai
tesorai.com
Commit Biologics
commitbio.com
Human Biome
human-biome.com
MedInTech
medintech.co.kr
Ace Padel
acepadel.com
Mentix
mentix.world